Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
cathepsin D CRISPR/Cas9 KO Plasmid (m): sc-419875
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- cathepsin D CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the cathepsin D genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: cathepsin D Antibody (D-7): sc-377299
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
cathepsin D CRISPR/Cas9 KO Plasmid (m) | sc-419875 | 20 µg | $397.00 |
Overview
Mouse Ctsd encodes cathepsin D, a lysosomal aspartyl endopeptidase central to intracellular protein turnover and endolysosomal homeostasis. Cathepsin D participates in autophagic flux, lysosome-mediated degradation, and processing of bioactive peptides, thereby influencing antigen processing and broader proteostasis networks. Disrupted CTSD activity is linked to lysosomal dysfunction, neuronal vulnerability, and altered inflammatory signaling, making it relevant for studies of neurodegeneration and metabolic stress responses. In cell and animal models, Ctsd is also used to interrogate crosstalk between lysosome function, apoptosis, and mitochondrial quality control pathways.
cathepsin D CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Ctsd gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Ctsd together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Ctsd open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish cathepsin D protein expression.
This CRISPR knockout system enables efficient generation of Ctsd-deficient cell models for investigation of cathepsin D signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Ctsd exon(s) critical for cathepsin D function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Ctsd genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by cathepsin D CRISPR/Cas9 KO Plasmid (m) and cathepsin D CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Ctsd locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by cathepsin D HDR Plasmid (m) and cathepsin D HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Ctsd homology arms to support homology-directed repair at defined Ctsd target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.